News | August 03, 2008

Abnormal Heart Rate Turbulence Predicts Sudden Death in Patients with CHF

August 4, 2008 – New research shows abnormal heart rate turbulence (HRT), an ECG-based risk marker, is a significant risk predictor for sudden death in patients with congestive heart failure (CHF).

The study published in the August edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, is the first to document abnormal HRT as an indicator of sudden, or arrhythmic death risk in patients with heart failure.

The MUSIC (Muerte Subita en Insufficiencia Cardiaca) Study, a multi-center, Spanish, longitudinal study designed to assess risk markers for sudden death in CHF patients, represents the largest heart failure population ever studied. More than 1,000 patients were enrolled in the MUSIC Study between 2003 and 2004 and several risk markers, including Holter-based, were assessed to predict mortality during nearly four years of follow up. Led by principal investigator Antoni Bayes de Luna, M.D., this is the first study to document that HRT predicts not only all-cause mortality and heart failure progression, but also sudden death in patients with heart failure.

“Our study documented that HRT might be considered a useful tool to identify heart failure patients at high risk of death, including high risk of dying suddenly,” said lead author Iwona Cygankiewicz, M.D., Ph.D., cardiology division, University of Rochester Medical Center in New York. “HRT may help physicians more effectively manage heart failure patients by indicating the need for more frequent follow up visits at specialized heart failure units and more intensely applied therapy, including ICD implantation in high risk patients.”

About 50 percent of congestive heart failure-related deaths are due to progressive heart failure, while the other half are thought to be related to serious arrhythmias. Even though HRT was proven as an important risk startifier in postinfarction patients, little is known about its value in patients with heart failure. Previous, smaller studies have proven abnormal HRT as a risk stratifier for all-cause mortality and heart failure progression, but not sudden death.

Patients of the MUSIC study represent a modern population of heart failure patients with a broad spectrum of etiologies. The study population includes patients with heart failure as seen at the ambulatory practice, including a high number of patients with preserved left ventricular ejection fraction (LVEF). Interest is growing in the survival of patients with preserved LVEF and the MUSIC study marks the first time this subgroup was included in a study evaluating the prognostic value of HRT.

For more information: www.heartrhythmjournal.com


Related Content

News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms ...

Home May 13, 2024
Home
Subscribe Now